Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms. We have arguably the richest and broadest pipeline in the industry with more than 65 New Molecular Entities in development.
Please select your therapy area of interest to connect to one of our specialist, partnering professionals.
Novartis Pharmaceuticals and Novartis Oncology research, develop and commercialize Innovative Medicines to enhance health outcomes for patients and HCPs.
Our Sandoz Division is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines.
Building a leading digital and data science platform through bold partnerships with industry leaders, and continuous investment in people and data management.
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19.
Co-developing AI Nurse, improving standards of care for heart failure patients in China.
We’re collaborating with AWS to build an enterprise-wide data and analytics platform to transform the way medicines are manufactured and delivered.
Phil Gotwals, the Head of BD&L at NIBR, talks about his vision for the future of business development for research.
A catalyst for impactful digital collaboration to create better healthcare solutions and seamless experiences for patients and caregivers, at scale.
Novartis and Microsoft announced a multiyear alliance which will leverage data & Artificial Intelligence (AI).
